Back to top
more

Neurocrine Biosciences (NBIX)

(Real Time Quote from BATS)

$147.78 USD

147.78
475,979

+3.65 (2.53%)

Updated Aug 8, 2024 01:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Neurocrine Biosciences Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Neurocrine Biosciences, Inc.

4 Defensive Stocks to Buy Amid Shutdown and Brexit

by Zacks Equity Research

Defensive equities could ride out market unpredictability.

Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

by Zacks Equity Research

Neurocrine (NBIX) issues preliminary sales outlook for Ingrezza with respect to the fourth quarter of 2018 as well as the full year. The company also lends an update on its pipeline.

Do Options Traders Know Something About Neurocrine Biosciences (NBIX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Neurocrine Biosciences (NBIX) stock based on the movements in the options market lately.

Neurocrine (NBIX) Catches Eye: Stock Jumps 6.5%

by Zacks Equity Research

Neurocrine (NBIX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of 8.33% and 0.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO

by Zacks Equity Research

We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.

Neurocrine (NBIX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are expected to focus on Neurocrine's (NBiX) updates on its pipeline candidates when it reports third-quarter results.

Neurocrine Biosciences (NBIX) Q3 Earnings Preview: What to Look Out For

by Zacks Equity Research

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Inks Deal with Private Biotech to Make CNS Drugs

by Zacks Equity Research

Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.

AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis

by Zacks Equity Research

AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.

    UTHR vs. NBIX: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    UTHR vs. NBIX: Which Stock Is the Better Value Option?

      Bayer Starts Phase III Study for Uterine Fibroids' Candidate

      by Zacks Equity Research

      Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.

        Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug

        by Zacks Equity Research

        Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).

          Company News for April 13, 2017

          by Zacks Equity Research

          Companies in the News are: BBRY,QCOM,VAL,AXTA,NBIX,NAK

            Parth Panchal headshot

            Here's Why Neurocrine (NBIX) Stock is Soaring 24% Today

            by Parth Panchal

            Neurocrine Biosciences (NBIX), a San Diego based biotechnology company, is soaring today on FDA approval of their drug INGREZZA (valbenazine).

              Repros' Proellex Continues to be Under Partial Clinical Hold

              by Zacks Equity Research

              Repros Therapeutics (RPRX) announced that the FDA will continue to maintain partial clinical hold on its pipeline candidate Proellex for uterine fibroids indication as the agency internally reviews data related to the effect of the same on the liver

                AbbVie's Elagolix Meets Primary Endpoint in Phase II Study

                by Zacks Equity Research

                AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.